MD Anderson Research Highlights: ESMO 2022 Special Edition

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. This special edition features upcoming oral presentations by MD Anderson researchers at the European Society for Medical Oncology (ESMO) Congress 2022 focused on clinical advances across a variety of cancer types. Highlights include promising early data from a novel T cell therapy for solid tumors, targeted therapy progress in rare and advanced cancers, biomarkers of immunotherapy response, and features associated with clinical outcomes in leptomeningeal disease. More information on ESMO content from MD Anderson can be found at MDAnderson.org/ESMO.

Transcutaneous Electrical Acustimulation for IBS-C, Infliximab Retreatment for Crohn’s Disease Featured in September Issue of AJG

The September issue of AJG highlights new clinical science, including a potential therapy to improve IBS-C symptoms, reintroduction of infliximab for Crohn’s disease, and population-based data to examine incidence and mortality of certain GI and hepatology diseases.

August Research Highlights

A Roundup of the Latest Medical Discoveries and Faculty News at Cedars-Sinai

MD Anderson Research Highlights for August 24, 2022

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include confirmation of improving response rates in Phase I trials over the last 20 years, a novel targeted therapy combination and biomarkers of response for chimeric antigen receptor (CAR) T cell therapy in B-cell lymphomas, a combination therapy for patients with melanoma brain metastases, and new treatment options for metastatic sarcomas, HPV-driven cancers and uterine cancer.

MD Anderson Research Highlights for July 27, 2022

Clinical advances include treating hematologic cancers with effective targeted therapies, circulating tumor DNA as a biomarker for recurrence with colorectal liver metastases, and using magnetic resonance imaging (MRI) to guide surgical decisions for patients with lateral pelvic lymph node metastases in rectal cancer. Laboratory findings offer new understanding of the pancreatic cancer immune microenvironment, melanoma cell states, TP53 mutation status in acute myeloid leukemia (AML), and potential targets for metastatic prostate cancer and GNAS-mutant colorectal cancer.

MD Anderson Research Highlights for July 13, 2022

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include new targets involved in protecting DNA replication forks and preventing inflammatory responses, a new treatment option for elderly patients with late-stage acute myeloid leukemia, insights into the breast cancer tumor microenvironment, biomarkers of response to targeted and immune therapies, a novel cellular therapy option for osteosarcoma and a new target for inducing ferroptosis in cancer cells.

Smartphone App to Assess Stool Form, Rural-Urban Disparities in Cirrhosis Mortality, Lung Infection Risk in Severe Alcoholic Hepatitis in July Issue of AJG

The July issue of The American Journal of Gastroenterology highlights new clinical science including using a smartphone app to assess stool form, rural-urban disparities in cirrhosis mortality, and lung infection risk in severe alcohol-related hepatitis. This issue also includes articles on pediatric IBD, therapy options for Crohn’s disease, a novel endoscopic suturing device, proton pump inhibitors, and more.

MD Anderson Research Highlights for June 29, 2022

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include a lower-intensity therapy for acute myeloid leukemia, a new target for treating chronic myelomonocytic leukemia, real-world synthetic controls for clinical trials in rare cancers, a potential biomarker to predict endocrine therapy response in breast cancer, integrated CRISPR screens to identify novel tumor suppressors, and a deeper knowledge of the immune tumor microenvironment in melanoma-derived brain metastases.

Five New Insights into the COVID-19 Pandemic’s Effects on Eating and Health

The COVID-19 pandemic affected people at all stages of life from seniors to newborns. New studies presented at NUTRITION 2022 LIVE ONLINE examine the causes and effects of COVID-19-related food insecurity, how the pandemic affected breastfeeding practices and more.

First-of-its-Kind Stem Cell and Gene Therapy Highlighted at Annual Stem Cell Meeting

Investigators from Cedars-Sinai will present the latest novel stem cell and regenerative medicine research at the International Society for Stem Cell Research (ISSCR) Annual Meeting, which is being held in person and virtually June 15-19 in San Francisco.

AJG Special Food as Medicine Issue Includes Pickle Juice Study, Guide to Alpha-Gal Meat Allergy, Digestive Health in Sexual and Gender Minority Populations and More

In a special Food as Medicine issue of The American Journal of Gastroenterology, Co-Editors-in-Chief Jasmohan S. Bajaj, MD, MS, FACG, and Millie D. Long, MD, MPH, FACG, have selected clinical studies, analyses, and reviews that aim to acknowledge the role of diet in disease management and prevention.

Studies reveal new insights into gut microbiome impact on immunotherapy response in multiple cancers, including glioblastoma

Two studies led by The University of Texas MD Anderson Cancer Center that shed new light on the potential of the gut microbiome as a targetable biomarker to improve responses to immunotherapy were presented today at the 2022 American Society for Clinical Oncology (ASCO) Annual Meeting.

HSS Presents Rheumatoid Arthritis Research at 2022 EULAR Annual Congress

At this year’s European Alliance of Associations for Rheumatology (EULAR) Congress, held June 1 to 4 in Copenhagen, Hospital for Special Surgery (HSS) presented new research related to the treatment and management of rheumatoid arthritis (RA). The studies focus on the tapering of treatment in patients whose disease is well controlled, real-world outcomes for targeted therapies, assessing the effects of biologic treatments on immune cells from patients with RA, and the underlying mechanisms of arthritis triggered by immune checkpoint therapies used to treat cancer.

MD Anderson researchers present cellular therapy advances at the 2022 ASCO Annual Meeting

Promising clinical results with cellular therapies for patients with blood cancers highlight advances being presented by researchers from The University of Texas MD Anderson Cancer Center at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

These findings include long-term outcomes of patients receiving an infusion of brexucabtagene autoleucel (KTE-X19) for mantle cell lymphoma, efficacy of gamma delta CAR T therapy for aggressive B-cell lymphoma and responses of umbilical cord blood-derived expanded natural killer cells when given together with combination therapy before stem cell transplant.

MD Anderson Research Highlights for June 1, 2022

Current advances include new biomarkers to predict chimeric antigen receptor (CAR) T cell therapy outcomes and neurotoxicities, novel treatment targets for pre-cancerous pancreatic lesions and T-cell acute lymphoblastic leukemia, a new approach to improve immunotherapy responses in cold tumors, a profile of synthetic lethal targets for cancers with tumor suppressor loss, and promising clinical data for acute myeloid leukemia and cancers of unknown primary.

MD Anderson Research Highlights: ASCO 2022 Special Edition

This special edition features upcoming oral presentations by MD Anderson researchers at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting focused on quality improvement, health services research, new treatments for skin cancers, and symptoms and survivorship advances. More information on ASCO content from MD Anderson can be found at MDAnderson.org/ASCO.

May Research Highlights

A Roundup of the Latest Medical Discoveries and Faculty News at Cedars-Sinai

MD Anderson Research Highlights for May 4, 2022

Featured studies include clinical advances with a new combination therapy targeting angiogenesis in platinum-resistant ovarian cancer and a promising immunotherapy combination for kidney cancer, plus laboratory studies that focus on targeting ferroptosis in specific lung cancers, developing chimeric antigen receptor (CAR) T cell therapies for blastic plasmacytoid dendritic cell neoplasms, and characterizing racial and ethnic disparities in breast cancer early detection.

Abdominal Bloating, Endoscopic Brushing, and Non-EoE Eosinophilic Conditions Addressed in the May Issue of The American Journal of Gastroenterology

The May issue of The American Journal of Gastroenterology features articles on abdominal bloating treatment, endoscopic brushing frequency to improve malignant biliary structure detection, and eosinophilic conditions not including eosinophilic esophagitis.

April Research Highlights

This tipsheet highlights the latest medical discoveries and faculty news at Cedars-Sinai. Links to full news releases are included with each item.

November Issue of The American Journal of Gastroenterology Discusses Association Between BMI and Early-Onset Colorectal Cancer Risk, PPIs and All-Cause Mortality

The November issue of The American Journal of Gastroenterology features several articles examining the association between common conditions or treatments and the risk for disease development, including a study on the association between higher body mass index and increased risk for early-onset colorectal cancer, and a population study on proton pump inhibitors and all-cause mortality.

MD Anderson Research Highlights for November 3, 2021

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include the cost-effectiveness of expanded lung cancer screening criteria, a novel biomarker for predicting immunotherapy responses, development of a technique for multiplex single-cell chromatin profiling, combination immunotherapy for bone metastatic prostate cancer, understanding drivers of lung cancer metastasis, and enabling new T cell therapies for treating COVID-19.

NYU Langone Presentations at American College of Rheumatology Convergence 2021 to Address Vaccine Efficacy and High-risk Pregnancy

NYU Langone rheumatologists are presenting their discoveries at the annual American College of Rheumatology conference, November 1 to November 9. The conference will be held virtually.

MD Anderson Research Highlights: ASTRO 2021 Special Edition

This special edition features oral presentations by MD Anderson researchers at the 2021 American Society for Radiation Oncology (ASTRO) Annual Meeting (Oct. 24-27) on novel therapeutic and diagnostic approaches, including partial breast irradiation, evaluating PD-L1 levels as biomarkers to better predict response to immunotherapy, and deep learning and biomechanical models.

Science snapshots from Berkeley Lab

New Berkeley Lab breakthroughs: engineering chemical-producing microbes; watching enzyme reactions in real time; capturing the first image of ‘electron ice’; revealing how skyrmions really move

MD Anderson Research Highlights for September 22, 2021

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include a new method to measure breast cancer response, a new immunotherapy approach for multiple myeloma, characterization of the immune landscape of cholangiocarcinoma, a new contrast agent to improve molecular imaging techniques, and new treatment targets in breast, gynecologic and pancreatic cancers.

MD Anderson Research Highlights: ESMO 2021 Special Edition

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent studies in basic, translational and clinical cancer research from MD Anderson experts. This special edition features oral presentations by MD Anderson researchers at the virtual European Society for Medical Oncology (ESMO) Congress 2021 on novel therapeutic approaches, including cell therapy for solid tumors, antibody drug conjugates targeting TROP2 and neoadjuvant pembrolizumab for advanced solid tumors with mismatch repair deficiencies.